In animal studies, resmetirom increases the expression of genes involved in fatty acid oxidation ( CPT1A , ACOX1 ), mitochondrial biogenesis ( PPARGC1A ), and cholesterol catabolism ( CYP7A1 ), while reducing levels of lipogenic targets ( SREBP-1c , FASN ) [1921]
52 Orforglipron showed to have a pharmacodynamic and safety profile similar to that of injectable GLP-1 which supported continued clinical development
Symptoms often intensify following each dose escalation
Recent studies show the FDA is now exploring GLP-1s as a potential medication-assisted treatment for addiction
This includes follow-up care, ongoing lifestyle coaching, and access to additional resources to ensure that patients have the tools they need to sustain their healthy habits and prevent weight regain
Meet the experts: Dr Kunal Shah is an assistant professor in the division of endocrinology at the Rutgers Robert Wood Johnson Medical Center